Although studies analyzing the potency of PD-1/PD-L1 inhibitors in the management of cervical cancer are rare, there are few studies on the clinical application of PD-1/PD-L1 inhibitors and/or new inhibitors targeting other elements of cell death program. Here, CD274 is linked to cervical cancer.